Raludotatug deruxtecan (R-DXd) earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab (Avastin; Genentech) treatment.
Jax DiEugenio
Advertisement
Articles by Jax DiEugenio
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
3
Rheumatoid Arthritis Linked to Elevated Pneumonia Risk, Especially in Seropositive Disease
4
Weighing Osimertinib vs Amivantamab-Lazertinib in Frontline EGFR NSCLC: Danny Nguyen, MD
5
